A Mechanistic Pilot Open-label Study to Evaluate the Effect of Benralizumab on Airway Function and Inflammation in Patients With Severe, Poorly-controlled Eosinophilic Asthma Using Inhaled Hyperpolarized 129-Xenon MRI
Phase of Trial: Phase II
Latest Information Update: 26 Apr 2019
Price : $35 *
At a glance
- Drugs Benralizumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms AERFLO
- 23 Apr 2019 Planned primary completion date changed from 1 Jun 2019 to 30 Nov 2019.
- 23 Apr 2019 Status changed from not yet recruiting to recruiting.
- 17 Nov 2018 New trial record